And the first step is early and accessible screening. RetinaLyze® is a screening software, which helps eye care professionals perform screenings for signs of eye diseases in a safe and efficient manner. The automated algorithm (AI) module detects possible signs of eye diseases by analyzing fundus images and OCT-scans. It can be used as a clinical decision support system (CDSS) or as a screening tool in conjunction with the telemedicine module.

The RetinaLyze® system combines the speed and efficiency of Artificial Intelligence with the guidance and supervision of telemedicine to dramatically lower the cost of eye screening and makes it possible to offer treatment to patients around the world at manageable costs. The RetinaLyze® system also enables retail eye care professionals such, as optometrists, to perform safe and easy eye screenings, thereby increasing the availability of eye-screenings for the general public.

A RetinaLyze screening is performed by capturing a fundus image or OCT-scan and uploading it to the RetinaLyze service. You can then run an analysis for signs of DR, AMD or Glaucoma on fundus photos and over 100 signs of eye diseases on OCT-scans. The results are shown to the operator within 30 seconds. The entire process can be initiated using a web-browser, internet connected software (such as EHR/EMR/Patient journal systems) or an internet connected fundus camera.

The result is given in four easy to understand colour codes: Red, Yellow or Green and Grey. Red, Yellow and Green indicates the severity of the found changes and Grey indicates that the image was not of acceptable image quality to perform the analysis. It will also be possible to see an overlay of the detected retinal changes on the fundus image.

When screening the general public, there will be no detected changes in 85-90% of the cases and the operator can store the image and ask the patient to return next year for a new test. 

In the event of detected retinal changes the image must be sent to a specialist, who will provide the operator with a manual assessment. In some cases the patient will be advised to contact a local ophthalmologist for further examination. This ophthalmologists then performs the final diagnosis and treatment.

The Retinalyze System consists of vector- and colorimetry-based algorithms. The patented invention relates to a method for assessing the presence or absence of retinal lesion(s) and damage to the optical nerve head in a fundus image. 

RetinaLyze can run multiple types of analyses (DR, AMD, Glaucoma and OCT).

RetinaLyze DR is made to focus on the detecting the early signs of Diabetic Retinopathy (NPDR). RetinaLyze DR detects micro-aneurysms and minor hemorrhages. Read more here: https://help.retinalyze.com/en/articles/1163418-retinalyze-dr

Retinalyze AMD is made to detect the early signs of Age-related Macular Degeneration, such as white lesions on the retina (Dry non-exudative AMD).

Read more here: https://help.retinalyze.com/en/articles/1163419-retinalyze-amd

RetinaLyze Glaucoma analyses a fundus image to detect signs of glaucoma. The algorithm works by measuring the hemoglobin (Hb) levels in the optic nerve head (ONH) by means of color fundus images (colorimetry).

Read more here: https://help.retinalyze.com/en/articles/1163519-retinalyze-glaucoma

RetinaLyze OCT analyses OCT scans and detects over 100 signs of pathology in 45 seconds. Read more here: https://help.retinalyze.com/en/articles/5505250-retinalyze-oct